<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360866</url>
  </required_header>
  <id_info>
    <org_study_id>331-10-238</org_study_id>
    <nct_id>NCT01360866</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)</brief_title>
  <acronym>Orion</acronym>
  <official_title>A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in
      addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major
      Depressive Disorder (MDD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">May 18, 2017</completion_date>
  <primary_completion_date type="Actual">April 18, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs) - All Participants</measure>
    <time_frame>From screening to week 52/early termination</time_frame>
    <description>To assess the frequency and severity of AEs as the variables of safety and tolerability of brexpiprazole.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) of Illness Score</measure>
    <time_frame>From screening to week 52/early termination</time_frame>
    <description>The severity of illness for each participant was rated using the CGI-S . On the basis of the investigator answer to the question: &quot;Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?&quot; Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Clinical Global Impression - Improvement (CGI-I) Score</measure>
    <time_frame>From screening to week 52/early termination</time_frame>
    <description>The efficacy of trial treatment was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the participant's condition at screening. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse and 7 = very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score</measure>
    <time_frame>From screening to week 52/early termination</time_frame>
    <description>The SDS was a self-rated instrument used to measure the effect of the participant's symptoms on regular life responsibilities. The SDS was a visual analogue scale that used spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the 3 domains with scores from 0 = not at all, to 10 = extremely.
Scores of 5 and above were associated with significant functional impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Inventory of Depressive Symptomatology - Self Report (IDS-SR) Total Score</measure>
    <time_frame>From screening to week 52/early termination</time_frame>
    <description>The IDS-SR was a 30-item self-report measure used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of MDD. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the &quot;best&quot; rating and 3 being the &quot;worst&quot; rating. The IDS-SR Total Score is the sum of ratings of 28 item scores. The possible IDS-SR Total Score ranges from 0 (best) to 84 (worst).
Under item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. If the number of items recorded is at least 23 and at most 27, the IDS-SR Total Score will be the mean of the recorded items multiplied by 28 and then rounded to the first decimal place.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">2944</enrollment>
  <condition>Depressive Disorder</condition>
  <condition>Depression</condition>
  <condition>Depressive Disorder, Major</condition>
  <condition>Mood Disorders</condition>
  <condition>Mental Disorders</condition>
  <arm_group>
    <arm_group_label>OPC-34712 (Brexpiprazole) and Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-34712: Oral tablet; 0.5 to 3 mg/day Escitalopram: Oral tablet; 10 or 20 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-34712 and Fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-34712: Oral tablet; 0.5 to 3 mg/day Fluoxetine: Oral capsules; 20 or 40 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-34712 and Paroxetine CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-34712: Oral tablet; 0.5 to 3 mg/day Paroxetine CR: Oral controlled-release tablets; 37.5 or 50 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-34712 and Sertraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-34712: Oral tablet; 0.5 to 3 mg/day Sertraline: Oral tablets; 100, 150, or 200 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-34712 and Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-34712: Oral tablet; 0.5 to 3 mg/day Duloxetine: Oral delayed-release capsules; 40 or 60 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-34712 and Venlafaxine XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-34712: Oral tablet; 0.5 to 3 mg/day Venlafaxine XR: Oral extended-release capsules; 75, 150, or 225 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-34712</intervention_name>
    <description>Tablet</description>
    <arm_group_label>OPC-34712 (Brexpiprazole) and Escitalopram</arm_group_label>
    <arm_group_label>OPC-34712 and Duloxetine</arm_group_label>
    <arm_group_label>OPC-34712 and Fluoxetine</arm_group_label>
    <arm_group_label>OPC-34712 and Paroxetine CR</arm_group_label>
    <arm_group_label>OPC-34712 and Sertraline</arm_group_label>
    <arm_group_label>OPC-34712 and Venlafaxine XR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Tablet</description>
    <arm_group_label>OPC-34712 (Brexpiprazole) and Escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Capsule</description>
    <arm_group_label>OPC-34712 and Fluoxetine</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine CR</intervention_name>
    <description>Controlled-release tablets</description>
    <arm_group_label>OPC-34712 and Paroxetine CR</arm_group_label>
    <other_name>Paxil CR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Tablets</description>
    <arm_group_label>OPC-34712 and Sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Delayed-release capsules</description>
    <arm_group_label>OPC-34712 and Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine XR</intervention_name>
    <description>Extended-release capsules</description>
    <arm_group_label>OPC-34712 and Venlafaxine XR</arm_group_label>
    <other_name>Effexor XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Female outpatients 18-65 years of age

        Eligible subjects from Trials 331-10-227, 331-10-228 or 331-12-282:

          -  Subjects who completed participation in the Double-blind Randomization Phase (i.e.
             Week 14 visit) in Trial 331-10-227, Trial 331-10-228, or Trial 331-12-282 or

          -  Subjects who met criteria for a response, but did not meet criteria for remission at
             Week 14 of either trial

        Eligible subjects from other Phase 3, Double-blind, Brexpiprazole MDD trials:

        • Subjects who completed the last scheduled visit of the prior Double-blind Randomized
        Phase 3 trial.

        Exclusion Criteria:

          -  Females who are breast-feeding and/or who have a positive pregnancy test result prior
             to receiving OPC-34712.

          -  Subjects with a major protocol violation during the course of their participation in
             the Double-blind Randomization Phase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Weymouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester Hills</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tom River</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bridgeville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodstock</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herndon</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brown Deer</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middleton</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gatineau</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penticton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pointe-Claire</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arcachon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Douai</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elancourt</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jarnac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orvault</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palaiseau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Achim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mittweida</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stralsund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belchatow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pruszcz Gdanski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tuszyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iași</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Târgu-Mureş</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arkhangelsk Region</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roshchino</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersberg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tonnel'nyy</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novi Knezevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Košice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Michalovce</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernihiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 24, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <results_first_submitted>May 25, 2018</results_first_submitted>
  <results_first_submitted_qc>September 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2018</results_first_posted>
  <last_update_submitted>September 14, 2018</last_update_submitted>
  <last_update_submitted_qc>September 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OPC-34712</keyword>
  <keyword>brexpiprazole</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Adjunctive Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 13, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT01360866/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT01360866/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was conducted in 2944 participants at 188 sites in 11 countries: Canada, France, Germany, Hungary, Poland, Romania, Russian Federation, Serbia, Slovakia, Ukraine, and United States (US).</recruitment_details>
      <pre_assignment_details>The study population consisted of eligible participants who completed one of the double-blind, phase 3 brexpiprazole major depressive disorder (MDD) trials and who, could potentially benefit from adjunctive treatment with oral brexpiprazole for MDD.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prior Placebo</title>
          <description>Participants who received placebo with antidepressant therapy [ADT] in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
        </group>
        <group group_id="P2">
          <title>Prior Brexpiprazole</title>
          <description>Participants who received Brexpiprazole with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
        </group>
        <group group_id="P3">
          <title>Prior ADT</title>
          <description>Participants who received only ADT in previous double blind phase 3 studies and were not randomized, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
        </group>
        <group group_id="P4">
          <title>Prior Seroquel</title>
          <description>Participants who received Seroquel with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="516"/>
                <participants group_id="P2" count="707"/>
                <participants group_id="P3" count="1645"/>
                <participants group_id="P4" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="420"/>
                <participants group_id="P3" count="1126"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
                <participants group_id="P2" count="287"/>
                <participants group_id="P3" count="519"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="134"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Paticipant met withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by participant</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="168"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>comprised of all participants who signed an informed consent form (ICF) for the trial.</population>
      <group_list>
        <group group_id="B1">
          <title>Prior Placebo</title>
          <description>Participants who received placebo with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
        </group>
        <group group_id="B2">
          <title>Prior Brexpiprazole</title>
          <description>Participants who received Brexpiprazole with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
        </group>
        <group group_id="B3">
          <title>Prior ADT</title>
          <description>Participants who received only ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
        </group>
        <group group_id="B4">
          <title>Prior Seroquel</title>
          <description>Participants who received Seroquel with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="516"/>
            <count group_id="B2" value="707"/>
            <count group_id="B3" value="1645"/>
            <count group_id="B4" value="76"/>
            <count group_id="B5" value="2944"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="11.0"/>
                    <measurement group_id="B2" value="45.0" spread="11.0"/>
                    <measurement group_id="B3" value="44.0" spread="12.0"/>
                    <measurement group_id="B4" value="44.0" spread="11.0"/>
                    <measurement group_id="B5" value="45.0" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="367"/>
                    <measurement group_id="B2" value="479"/>
                    <measurement group_id="B3" value="1108"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="2005"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="228"/>
                    <measurement group_id="B3" value="537"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="452"/>
                    <measurement group_id="B2" value="609"/>
                    <measurement group_id="B3" value="1459"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="2588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events (AEs) - All Participants</title>
        <description>To assess the frequency and severity of AEs as the variables of safety and tolerability of brexpiprazole.</description>
        <time_frame>From screening to week 52/early termination</time_frame>
        <population>Participants who received at least one dose of open-label brexpiprazole as adjunctive therapy to one of the allowed ADTs.</population>
        <group_list>
          <group group_id="O1">
            <title>Prior Placebo</title>
            <description>Participants who received placebo with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O2">
            <title>Prior Brexpiprazole</title>
            <description>Participants who received Brexpiprazole with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O3">
            <title>Prior ADT</title>
            <description>Participants who received only ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O4">
            <title>Prior Seroquel</title>
            <description>Participants who received Seroquel with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AEs) - All Participants</title>
          <description>To assess the frequency and severity of AEs as the variables of safety and tolerability of brexpiprazole.</description>
          <population>Participants who received at least one dose of open-label brexpiprazole as adjunctive therapy to one of the allowed ADTs.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="706"/>
                <count group_id="O3" value="1640"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400"/>
                    <measurement group_id="O2" value="511"/>
                    <measurement group_id="O3" value="1165"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with treatment emergent AE (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399"/>
                    <measurement group_id="O2" value="510"/>
                    <measurement group_id="O3" value="1163"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partcipants discontinued due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="134"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) of Illness Score</title>
        <description>The severity of illness for each participant was rated using the CGI-S . On the basis of the investigator answer to the question: &quot;Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?&quot; Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.</description>
        <time_frame>From screening to week 52/early termination</time_frame>
        <population>Participants who received at least one dose of open-label brexpiprazole as adjunctive therapy to one of the allowed ADTs and had at least one post-baseline efficacy evaluation of CGI-S.</population>
        <group_list>
          <group group_id="O1">
            <title>Prior Placebo</title>
            <description>Participants who received placebo with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O2">
            <title>Prior Brexpiprazole</title>
            <description>Participants who received Brexpiprazole with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O3">
            <title>Prior ADT</title>
            <description>Participants who received only ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O4">
            <title>Prior Seroquel</title>
            <description>Participants who received Seroquel with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) of Illness Score</title>
          <description>The severity of illness for each participant was rated using the CGI-S . On the basis of the investigator answer to the question: &quot;Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?&quot; Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.</description>
          <population>Participants who received at least one dose of open-label brexpiprazole as adjunctive therapy to one of the allowed ADTs and had at least one post-baseline efficacy evaluation of CGI-S.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="698"/>
                <count group_id="O3" value="1630"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="1.11"/>
                    <measurement group_id="O2" value="-0.63" spread="1.16"/>
                    <measurement group_id="O3" value="-0.48" spread="1.04"/>
                    <measurement group_id="O4" value="-0.93" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Clinical Global Impression - Improvement (CGI-I) Score</title>
        <description>The efficacy of trial treatment was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the participant's condition at screening. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse and 7 = very much worse.</description>
        <time_frame>From screening to week 52/early termination</time_frame>
        <population>Participants who received at least one dose of open-label brexpiprazole as adjunctive therapy to one of the allowed ADTs and had at least one post-baseline efficacy evaluation of CGI-S.</population>
        <group_list>
          <group group_id="O1">
            <title>Prior Placebo</title>
            <description>Participants who received placebo with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O2">
            <title>Prior Brexpiprazole</title>
            <description>Participants who received Brexpiprazole with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O3">
            <title>Prior ADT</title>
            <description>Participants who received only ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O4">
            <title>Prior Seroquel</title>
            <description>Participants who received Seroquel with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Clinical Global Impression - Improvement (CGI-I) Score</title>
          <description>The efficacy of trial treatment was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the participant's condition at screening. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse and 7 = very much worse.</description>
          <population>Participants who received at least one dose of open-label brexpiprazole as adjunctive therapy to one of the allowed ADTs and had at least one post-baseline efficacy evaluation of CGI-S.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
                <count group_id="O2" value="693"/>
                <count group_id="O3" value="1606"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="1.30"/>
                    <measurement group_id="O2" value="2.63" spread="1.34"/>
                    <measurement group_id="O3" value="2.63" spread="1.39"/>
                    <measurement group_id="O4" value="2.40" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score</title>
        <description>The SDS was a self-rated instrument used to measure the effect of the participant's symptoms on regular life responsibilities. The SDS was a visual analogue scale that used spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the 3 domains with scores from 0 = not at all, to 10 = extremely.
Scores of 5 and above were associated with significant functional impairment.</description>
        <time_frame>From screening to week 52/early termination</time_frame>
        <population>Participants who received at least one dose of open-label brexpiprazole as adjunctive therapy to one of the allowed ADTs and had at least one post-baseline efficacy evaluation of CGI-S.</population>
        <group_list>
          <group group_id="O1">
            <title>Prior Placebo</title>
            <description>Participants who received placebo with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O2">
            <title>Prior Brexpiprazole</title>
            <description>Participants who received Brexpiprazole with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O3">
            <title>Prior ADT</title>
            <description>Participants who received only ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O4">
            <title>Prior Seroquel</title>
            <description>Participants who received Seroquel with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score</title>
          <description>The SDS was a self-rated instrument used to measure the effect of the participant's symptoms on regular life responsibilities. The SDS was a visual analogue scale that used spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the 3 domains with scores from 0 = not at all, to 10 = extremely.
Scores of 5 and above were associated with significant functional impairment.</description>
          <population>Participants who received at least one dose of open-label brexpiprazole as adjunctive therapy to one of the allowed ADTs and had at least one post-baseline efficacy evaluation of CGI-S.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="457"/>
                <count group_id="O3" value="1165"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="2.80"/>
                    <measurement group_id="O2" value="-0.70" spread="2.60"/>
                    <measurement group_id="O3" value="-0.40" spread="2.30"/>
                    <measurement group_id="O4" value="-1.00" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Inventory of Depressive Symptomatology - Self Report (IDS-SR) Total Score</title>
        <description>The IDS-SR was a 30-item self-report measure used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of MDD. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the &quot;best&quot; rating and 3 being the &quot;worst&quot; rating. The IDS-SR Total Score is the sum of ratings of 28 item scores. The possible IDS-SR Total Score ranges from 0 (best) to 84 (worst).
Under item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. If the number of items recorded is at least 23 and at most 27, the IDS-SR Total Score will be the mean of the recorded items multiplied by 28 and then rounded to the first decimal place.</description>
        <time_frame>From screening to week 52/early termination</time_frame>
        <population>Participants who received at least one dose of open-label brexpiprazole as adjunctive therapy to one of the allowed ADTs and had at least one post-baseline efficacy evaluation of CGI-S.</population>
        <group_list>
          <group group_id="O1">
            <title>Prior Placebo</title>
            <description>Participants who received placebo with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O2">
            <title>Prior Brexpiprazole</title>
            <description>Participants who received Brexpiprazole with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O3">
            <title>Prior ADT</title>
            <description>Participants who received only ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
          <group group_id="O4">
            <title>Prior Seroquel</title>
            <description>Participants who received Seroquel with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Inventory of Depressive Symptomatology - Self Report (IDS-SR) Total Score</title>
          <description>The IDS-SR was a 30-item self-report measure used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of MDD. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the &quot;best&quot; rating and 3 being the &quot;worst&quot; rating. The IDS-SR Total Score is the sum of ratings of 28 item scores. The possible IDS-SR Total Score ranges from 0 (best) to 84 (worst).
Under item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. If the number of items recorded is at least 23 and at most 27, the IDS-SR Total Score will be the mean of the recorded items multiplied by 28 and then rounded to the first decimal place.</description>
          <population>Participants who received at least one dose of open-label brexpiprazole as adjunctive therapy to one of the allowed ADTs and had at least one post-baseline efficacy evaluation of CGI-S.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
                <count group_id="O2" value="664"/>
                <count group_id="O3" value="1556"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.25" spread="12.21"/>
                    <measurement group_id="O2" value="-4.76" spread="11.79"/>
                    <measurement group_id="O3" value="-3.94" spread="10.57"/>
                    <measurement group_id="O4" value="-7.44" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening to 30 (+ 2) days following the 52 weeks treatment period or early termination.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug-related.
An AE was considered serious if it resulted in any of the following outcomes: fatal; life threatening; persistently or significantly disabling or incapacitating; required inpatient hospitalization or prolonged existing hospitalization; a congenital anomaly/birth defect; or other medically significant event</desc>
      <group_list>
        <group group_id="E1">
          <title>Prior Placebo</title>
          <description>Participants who received placebo with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
        </group>
        <group group_id="E2">
          <title>Prior Brexpiprazole</title>
          <description>Participants who received Brexpiprazole with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
        </group>
        <group group_id="E3">
          <title>Prior ADT</title>
          <description>Participants who received only ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
        </group>
        <group group_id="E4">
          <title>Prior Seroquel</title>
          <description>Participants who received Seroquel with ADT in previous double blind phase 3 studies, received 0.5 to 3 mg/day Brexpiprazole + ADT for weeks 1, 2, 4, 8,14, 20, 26, 32, 38, 44 and 52 with dose adjustment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Ventricular Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Retinal Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Drug Withdrawal Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hepatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Kidney Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram Qt Prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Intraductal Proliferative Breast Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pancreatic Neuroendocrine Tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Rectal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Extrapyramidal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Lumbar Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Ruptured Cerebral Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Depressive Symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Intentional Self-Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="296" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="323" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="787" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>General Disorders and Administration Site Conditions</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="296" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="130" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="1640"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Development</name_or_title>
      <organization>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</organization>
      <phone>609 524 6788</phone>
      <email>clinicaltransparency@otsuka-us.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

